Skip to main content
SpringerLink
Log in

Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours

  • Brief Report
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers.

Methods

Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were invited to answer survey questions related to their demographic, experience, and preferences as they relate to the real-world use of injectable SRL devices. Questions were developed based on review of available literature and meetings with a Scientific Committee.

Results

Device attributes preferred by the patient/non-HCP caregiver group (n = 211) included confidence that the correct drug amount is delivered (76%), quick administration with minimal pain/discomfort (68%), and device safety (needle-safety and low risk of contamination; 53%). Device attributes preferred by HCPs (n = 52) were quick administration with minimal pain/discomfort (69%), correct use is easy to learn, confidence in handling the device (63%), and confidence that the correct drug amount is delivered (62%).

Conclusion

The results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10:804–26.

    Article  CAS  PubMed  Google Scholar 

  2. O’Toole D, Kunz PL, Webb SM, et al. PRESTO 2: an international survey to evaluate patients’ injection experiences with the latest devices/formulations of long-acting somatostatin analog therapies for neuroendocrine tumors or acromegaly. Adv Ther. 2023;40:671–90.

    Article  CAS  PubMed  Google Scholar 

  3. Raimer-Hall D, Shea HC. Evolution of growth hormone devices: matching devices with patients. Pediatr Nurs. 2015;41:72–7.

    PubMed  Google Scholar 

  4. Gau M, Takasawa K. Initial patient choice of a growth hormone device improves child and adolescent adherence to and therapeutic effects of growth hormone replacement therapy. J Pediatr Endocrinol Metab. 2017;30:989–93.

    Article  CAS  PubMed  Google Scholar 

  5. Rohrer TR, Horikawa R, Kappelgaard AM. Growth hormone delivery devices: current features and potential for enhanced treatment adherence. Expert Opin Drug Deliv. 2017;14:1253–64.

    Article  CAS  PubMed  Google Scholar 

  6. Chang HJ, Huang K, Wu C. Determination of sample size in using central limit theorem for Weibull distribution. Int J Inf Manag Sci. 2006;17:153–247.

    Google Scholar 

  7. Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl). 2012;5:103–9.

    CAS  PubMed  Google Scholar 

  8. Ryan P, Phan AT, Adelman DT, Iwasaki M. Neuroendocrine tumors and lanreotide depot: clinical considerations and nurse and patient preferences. Clin J Oncol Nurs. 2016;20:E139–46.

    Article  PubMed  Google Scholar 

  9. Strasburger CJ, Karavitaki N, Störmann S, et al. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol. 2016;174:355–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Adelman DT, Van Genechten D, Megret CM, Truong Thanh XT, Hand P, Martin WA. Co-creation of a lanreotide autogel/depot syringe for the treatment of acromegaly and neuroendocrine tumours through collaborative human factor studies. Adv Ther. 2019;36:3409–23.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Adelman D, Truong Thanh XM, Feuilly M, Houchard A, Cella D. Evaluation of nurse preferences between the lanreotide autogel new syringe and the octreotide long-acting release syringe: an international simulated-use study (PRESTO). Adv Ther. 2020;37:1608–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Darden C, Price M, Ray D, et al. Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors. J Patient Rep Outcomes. 2021;5:82.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Delemer B, Nguyen-Tan-Hon T, Coriat R, et al. Evaluation of Nurses’ and patients’ overall satisfaction with new and previous formulations of octreotide long-acting release (Sandostatin LAR®): a French observational study. Adv Ther. 2020;37:3901–15.

    Article  CAS  PubMed  Google Scholar 

  14. Cella D, Evans J, Feuilly M, et al. Patient and healthcare provider perspectives of first-generation somatostatin analogs in the management of neuroendocrine tumors and acromegaly: a systematic literature review. Adv Ther. 2021;38:969–93.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Boguszewski CL, Korbonits M, Artignan A, et al. Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review. Endocrine. 2023;79:527–36.

    Article  CAS  PubMed  Google Scholar 

  16. Hernando J, Kolarova T, Verslype C, et al. HomeLAN: an international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumours (NETs) enrolled in lanreotide autogel (LAN) patient support programmes (PSPs). J Neuroendocrinol. 2022;34:176–86.

    Google Scholar 

  17. Debon R, Coleone JD, Bellei EA, De Marchi ACB. Mobile health applications for chronic diseases: a systematic review of features for lifestyle improvement. Diabetes Metab Syndr. 2019;13:2507–12.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Author Contribution

Jens Otto L. Jørgensen, Wouter W. de Herder, Wendy A. Martin, Teodora Kolarova, Muriël Marks, Cecilia Follin, Wanda Geilvoet, and Shlomo Melmed all worked on designing the survey, analysed the data, and contributed to the writing of the paper. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding

This work, including the journal’s Rapid Service fee, was supported by an independent educational grant from Ipsen. Ipsen had no role in the study design, data collection, analysis, interpretation, or writing of the report. Ipsen reviewed this manuscript for scientific accuracy but had no input into the content.

Medical Writing Assistance

Medical writing assistance in the preparation of this article was provided by Daniel Guns, MSc, from COR2ED, Basel, Switzerland. This assistance was funded by Ipsen.

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

The anonymous survey was exempted from institutional review board (IRB) approval in accordance with Association for Accreditation of Human Research Protection Programs, Inc. (AAHRPP) protocols (IRB Protocol ID: STUDY00002226; Approval Effective Date: July 6, 2022).

Conflict of Interest

Jens Otto L. Jørgensen has received grants and/or honoraria from Novo Nordisk, Pfizer. Wouter W. de Herder has received grants and/or honoraria from Ipsen, Novartis AAA. Wendy A. Martin has received honoraria from Ipsen. Teodora Kolarova (International Neuroendocrine Cancer Alliance [INCA]) has received grants from Novartis, Ipsen, ITM. Muriël Marks has nothing to disclose. Cecilia Follin has nothing to disclose. Wanda Geilvoet has nothing to disclose. Shlomo Melmed has received grants and/or honoraria from Ionos, Ipsen, Novo Nordisk, Pfizer.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

    Jens Otto L. Jørgensen

  2. Department of Internal Medicine-Endocrinology, Erasmus University Medical Centre, Rotterdam, Netherlands

    Wouter W. de Herder & Wanda Geilvoet

  3. King’s College Hospital, London, UK

    Wendy A. Martin

  4. International Neuroendocrine Cancer Alliance (INCA), Boston, MA, USA

    Teodora Kolarova

  5. World Alliance of Pituitary Organizations (WAPO), Amsterdam, Netherlands

    Muriël Marks

  6. Lund University Cancer Centre, Lund, Sweden

    Cecilia Follin

  7. Pituitary Center, Dept of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Shlomo Melmed

Authors
  1. Jens Otto L. Jørgensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wouter W. de Herder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wendy A. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teodora Kolarova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muriël Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cecilia Follin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wanda Geilvoet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shlomo Melmed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jens Otto L. Jørgensen.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 245 KB)

Supplementary file2 (PDF 236 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jørgensen, J.O.L., de Herder, W.W., Martin, W.A. et al. Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours. Adv Ther 40, 4675–4688 (2023). https://doi.org/10.1007/s12325-023-02627-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-023-02627-6

Keywords

Search

Navigation